We provide the latest news
from the world of economics and finance
(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine company, Wednesday announced the pricing of its public offering of 10.93 million common shares and pre-funded warrants to purchase 781,250 shares of common stock.
The common shares are priced at $64.00 per share and the pre-funded warrants at $63.999, with an exercise price of $0.001 per share.
Underwriters have the option for a 30 days period to purchase up to an additional 1,757,812 shares of the company's common stock at the public offering price.
BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities and Cantor are serving as the joint book running managers for the offering. BTIG and Needham & Company are acting as lead managers for the offering.
The offering is expected to close on February 2, 2024.
On Tuesday, Vaxcyte shares closed at $66 down 2% on the Nasdaq in the after hours.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.